A real-world comparison of tisagenlecleucel ...
Document type :
Article dans une revue scientifique: Article original
PMID :
Permalink :
Title :
A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma.
Author(s) :
Bachy, E. [Auteur]
Le Gouill, S. [Auteur]
Di Blasi, R. [Auteur]
Sesques, P. [Auteur]
Manson, G. [Auteur]
Cartron, G. [Auteur]
Beauvais, David [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Roulin, L. [Auteur]
Gros, F. X. [Auteur]
Rubio, M. T. [Auteur]
Bories, P. [Auteur]
Bay, J. O. [Auteur]
Llorente, C. C. [Auteur]
Choquet, S. [Auteur]
Casasnovas, R. O. [Auteur]
Mohty, M. [Auteur]
Guidez, S. [Auteur]
Joris, M. [Auteur]
Loschi, M. [Auteur]
Carras, S. [Auteur]
Abraham, J. [Auteur]
Chauchet, A. [Auteur]
Drieu La Rochelle, L. [Auteur]
Deau-Fischer, B. [Auteur]
Hermine, O. [Auteur]
Gastinne, T. [Auteur]
Tudesq, J. J. [Auteur]
Gat, E. [Auteur]
Broussais, F. [Auteur]
Thieblemont, C. [Auteur]
Houot, R. [Auteur]
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
Le Gouill, S. [Auteur]
Di Blasi, R. [Auteur]
Sesques, P. [Auteur]
Manson, G. [Auteur]
Cartron, G. [Auteur]
Beauvais, David [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Roulin, L. [Auteur]
Gros, F. X. [Auteur]
Rubio, M. T. [Auteur]
Bories, P. [Auteur]
Bay, J. O. [Auteur]
Llorente, C. C. [Auteur]
Choquet, S. [Auteur]
Casasnovas, R. O. [Auteur]
Mohty, M. [Auteur]
Guidez, S. [Auteur]
Joris, M. [Auteur]
Loschi, M. [Auteur]
Carras, S. [Auteur]
Abraham, J. [Auteur]
Chauchet, A. [Auteur]
Drieu La Rochelle, L. [Auteur]
Deau-Fischer, B. [Auteur]
Hermine, O. [Auteur]
Gastinne, T. [Auteur]
Tudesq, J. J. [Auteur]
Gat, E. [Auteur]
Broussais, F. [Auteur]
Thieblemont, C. [Auteur]
Houot, R. [Auteur]
Morschhauser, Franck [Auteur]

Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
Journal title :
Nature Medicine
Abbreviated title :
Nat Med
Volume number :
28
Pages :
2145-2154
Publisher :
Nature medicine group
Publication date :
2022-09-24
ISSN :
1546-170X
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) have both demonstrated impressive clinical activity in relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). In this study, we analyzed the outcome ...
Show more >Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) have both demonstrated impressive clinical activity in relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). In this study, we analyzed the outcome of 809 patients with R/R DLBCL after two or more previous lines of treatment who had a commercial chimeric antigen receptor (CAR) T cells order for axi-cel or tisa-cel and were registered in the retrospective French DESCAR-T registry study (NCT04328298). After 1:1 propensity score matching (n = 418), the best overall response rate/complete response rate (ORR/CRR) was 80%/60% versus 66%/42% for patients treated with axi-cel compared to tisa-cel, respectively (P < 0.001 for both ORR and CRR comparisons). After a median follow-up of 11.7 months, the 1-year progression-free survival was 46.6% for axi-cel and 33.2% for tisa-cel (hazard ratio (HR) = 0.61; 95% confidence interval (CI), 0.46–0.79; P = 0.0003). Overall survival (OS) was also significantly improved after axi-cel infusion compared to after tisa-cel infusion (1-year OS 63.5% versus 48.8%; HR = 0.63; 95% CI, 0.45–0.88; P = 0.0072). Similar findings were observed using the inverse probability of treatment weighting statistical approach. Grade 1–2 cytokine release syndrome was significantly more frequent with axi-cel than with tisa-cel, but no significant difference was observed for grade ≥3. Regarding immune effector cell-associated neurotoxicity syndrome (ICANS), both grade 1–2 and grade ≥3 ICANS were significantly more frequent with axi-cel than with tisa-cel. In conclusion, our matched comparison study supports a higher efficacy and also a higher toxicity of axi-cel compared to tisa-cel in the third or more treatment line for R/R DLBCL.Show less >
Show more >Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) have both demonstrated impressive clinical activity in relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). In this study, we analyzed the outcome of 809 patients with R/R DLBCL after two or more previous lines of treatment who had a commercial chimeric antigen receptor (CAR) T cells order for axi-cel or tisa-cel and were registered in the retrospective French DESCAR-T registry study (NCT04328298). After 1:1 propensity score matching (n = 418), the best overall response rate/complete response rate (ORR/CRR) was 80%/60% versus 66%/42% for patients treated with axi-cel compared to tisa-cel, respectively (P < 0.001 for both ORR and CRR comparisons). After a median follow-up of 11.7 months, the 1-year progression-free survival was 46.6% for axi-cel and 33.2% for tisa-cel (hazard ratio (HR) = 0.61; 95% confidence interval (CI), 0.46–0.79; P = 0.0003). Overall survival (OS) was also significantly improved after axi-cel infusion compared to after tisa-cel infusion (1-year OS 63.5% versus 48.8%; HR = 0.63; 95% CI, 0.45–0.88; P = 0.0072). Similar findings were observed using the inverse probability of treatment weighting statistical approach. Grade 1–2 cytokine release syndrome was significantly more frequent with axi-cel than with tisa-cel, but no significant difference was observed for grade ≥3. Regarding immune effector cell-associated neurotoxicity syndrome (ICANS), both grade 1–2 and grade ≥3 ICANS were significantly more frequent with axi-cel than with tisa-cel. In conclusion, our matched comparison study supports a higher efficacy and also a higher toxicity of axi-cel compared to tisa-cel in the third or more treatment line for R/R DLBCL.Show less >
Language :
Anglais
Audience :
Internationale
Administrative institution(s) :
Université de Lille
CHU Lille
CHU Lille
Collections :
Submission date :
2023-05-25T02:26:57Z
2023-06-28T09:41:23Z
2023-06-28T09:41:23Z
Files
- s41591-022-01969-y.pdf
- Non spécifié
- Open access
- Access the document